Test Price
2,800 AED✅ Home Collection Available
LFNG Gene Spondylocostal Dysostosis, Autosomal Recessive Type 3 DNA Test in UAE
Executive Summary & Core Metrics
Executive Summary: This clinically accredited NGS test identifies pathogenic variants in the LFNG gene, delivering a decisive diagnosis for spondylocostal dysostosis type 3 with 99.9% diagnostic sensitivity through ISO 9001:2015-certified processing.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Complimentary telephonic post-test clinical result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This next-generation sequencing analysis detects mutations in the LFNG gene responsible for autosomal recessive spondylocostal dysostosis type 3 – a severe congenital disorder of vertebral segmentation. Conducted on whole blood or extracted DNA, the test provides a definitive molecular diagnosis within 3 to 4 weeks, enabling early orthopaedic and respiratory management. The methodology employs the Illumina NGS platform with orthogonal Sanger validation to ensure 99.9% clinical sensitivity and specificity for all coding exons and flanking intronic regions.
| Feature | Our Test (ISO-Lab) | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing with 99.9% sensitivity | Panel test may miss rare LFNG variants |
| Methodology | NGS (Illumina platform) verified by Sanger | Research-grade exome without validation |
| Speed | Report within 3–4 weeks, cold-chain home collection | ≥6 weeks via overseas shipping |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh (Consultant Medical Genetics, DHA Registration ID: 9294403) advises: “A confirmed pathogenic variant in the LFNG gene provides a definitive molecular diagnosis for spondylocostal dysostosis type 3, enabling families and clinicians to initiate early surveillance for scoliosis and restrictive lung disease. This genetic result must be integrated with clinical imaging and physical examination to guide management. It is a tool for proactive care, not a verdict.”
Advisory Notice
⚠ Pre-Test Counselling Required
All patients and guardians must receive pre-test genetic counselling to discuss the scope of results, implications for family members, and the voluntary nature of testing. Do not discontinue any prescribed vitamin A or retinoid therapy without consulting your specialist, as these may influence vertebral development in affected foetuses.
Exclusion Criteria & Emergency Red Flags
- Neonates requiring immediate respiratory support – refer to tertiary NICU before phlebotomy.
- Active haemolysis or platelet disorder contraindicating venipuncture.
- Signs of acute spinal cord compromise (new-onset leg weakness, bladder dysfunction) – call 998 immediately.
- Known allergy to latex (notify phlebotomist for latex-free kit).
Patient FAQ & Clinical Guidance
1. What does a positive LFNG test mean for my child's future mobility?
A positive result confirms the genetic cause of spondylocostal dysostosis type 3, enabling precise prognosis and early intervention such as spinal bracing or surgical correction. Early detection allows a multidisciplinary team to create a tailored care plan that maximises functional outcomes.
2. Can this DNA test be performed on a newborn's cord blood?
Yes; cord blood or a single drop on an FTA card is acceptable. Our paediatric home collection team is trained for safe neonatal phlebotomy, and all samples are processed under the same ISO-accredited protocol.
3. How are my genetic data protected under UAE law?
All samples and genomic information are handled in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring full encryption, consent-based processing, and zero third-party sharing.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA). All genetic data are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic privacy is safeguarded with enterprise-grade encryption and access controls.
Clinical & Logistical Metadata
| Test Name | LFNG Gene Spondylocostal Dysostosis, Autosomal Recessive Type 3 DNA Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole Blood or Extracted DNA |
| Methodology Used | NGS (Illumina) with Sanger Confirmation |
| ICD-10-CM Code | Q76.49, Q76.3 |
| LOINC Code | 81255-6 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians